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ABSTRACT
The American College of Cardiology Foundation, in collab-
oration with the Society for Cardiovascular Angiography
and Interventions and key specialty and subspecialty socie-
ties, conducted a review of common clinical scenarios
where diagnostic catheterization is frequently considered.
The indications (clinical scenarios) were derived from
common applications or anticipated uses, as well as from
current clinical practice guidelines and results of studies ex-
amining the implementation of noninvasive imaging appro-
priate use criteria. The 166 indications in this document
were developed by a diverse writing group and scored by
a separate independent technical panel on a scale of 1 to
9, to designate appropriate use (median 7 to 9), uncertain
use (median 4 to 6), and inappropriate use (median 1 to 3).
Diagnostic catheterization may include several different
procedure components. The indications developed focused
primarily on 2 aspects of diagnostic catheterization.Many in-
dications focused on the performance of coronary angiogra-
phy for the detection of coronary artery disease with other
procedure components (eg, hemodynamic measurements,
ventriculography) at the discretion of the operator. The ma-
jority of the remaining indications focused on hemodynamic
measurements to evaluate valvular heart disease, pulmonary
hypertension, cardiomyopathy, and other conditions, with
the use of coronary angiography at the discretion of the oper-
ator. Seventy-five indications were rated as appropriate, 49
were rated as uncertain, and 42 were rated as inappropriate.
The appropriate use criteria for diagnostic catheterization
have the potential to impact physician decision making,
healthcare delivery, and reimbursement policy. Furthermore,
recognition of uncertain clinical scenarios facilitates identifi-
cation of areas that would benefit from future research.
PREFACE
In an effort to respond to the need for the rational use of
cardiovascular services, including imaging and invasive
procedures in the delivery of high-quality care, the Ameri-
can College of Cardiology Foundation (ACCF) inry c July 2012
Patel et al Clinical Guidelinescollaboration with other professional organizations has un-
dertaken a process to determine the appropriate use of car-
diovascular procedures for selected patient indications.
Appropriate use criteria (AUC) publications reflect an on-
going effort to critically and systematically create, review,
and categorize clinical situations where diagnostic tests
and therapeutic procedures are utilized by physicians caring
for patients with cardiovascular disease. The process is based
on understanding the technical capabilities of the procedures
examined. The diversity of clinical disease present makes it
difficult to be comprehensive, but the indications presented
hopefully identify common scenarios encompassing the ma-
jority of situations encountered in contemporary practice.
Given the breadth of information conveyed, the indications
do not directly correspond to the Ninth Revision of the Inter-
national Classification of Diseases system as these codes do
not include clinical information, such as symptom status.
The ACCF and the Society for Cardiovascular Angiogra-
phy and Interventions (SCAI) believe that careful blending
of a broad range of clinical experiences and available
evidence-based information will help guide a more efficient
and equitable allocation of healthcare resources in cardiovas-
cular care and invasive catheterization. The ultimate objec-
tive of the AUC is to improve patient care and health
outcomes in a cost-effective manner while recognizing that
some ambiguity and nuance is intrinsic to clinical decision
making. Therefore, the AUC should not be considered sub-
stitutes for sound clinical judgment and practice experience.
However, when the clinical judgment and practice patterns
routinely conflict with AUC ratings, further evaluation of
the specific clinical circumstances should be considered.
The AUC development process itself is also evolving.
Given the iterative nature of the process and incorporation
of new information about the role for diagnostic and thera-
peutic interventions, readers are counseled that comparison
of individual appropriate use ratings developed at different
times over the past several years may not reflect the compar-
ative utility of different modalities for a given indication, as
the ratingsmay vary over time. Cardiac catheterization plays
a central role in the care of patients with cardiovascular dis-
ease, and guidance around the rationale and evidence based
use of the procedure is the goal of the current document.
We are grateful to the technical panel and its moderator,
Pamela S. Douglas, MD, MACC, FAHA, FASE, a profes-
sional group with a wide range of skills and insights, for
their thoughtful and thorough deliberation of the merits of
diagnostic catheterization for various indications. We
would also like to thank the 28 individuals who provided
a careful review of the draft of indications, the parent
AUC Task Force, and the ACCF staff, specifically Joseph
M. Allen and Lea Binder for their exceptionally skilled sup-
port in the generation of this document.
Manesh R. Patel, MD, FACC
Co-Chair, Diagnostic Catheterization Writing GroupThe Journal of Thoracic and CSteven R. Bailey, MD, FACC, FSCAI, FAHA
Co-Chair, Diagnostic Catheterization Writing Group
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force1. INTRODUCTION
The ACCF, in collaboration with SCAI and several other
professional organizations, developed common clinical sce-
narios where diagnostic cardiac catheterization is fre-
quently considered. The indications, as presented in these
clinical scenarios, were derived from common presenta-
tions or anticipated uses, as well as from current clinical
practice guidelines. The 166 indications in this document
were developed by a writing group with diverse clinical ex-
pertise and scored by a separate independent technical panel
on a scale of 1 to 9, to designate appropriate use (median
scores 7 to 9), uncertain use (median scores 4 to 6), and in-
appropriate use (median scores 1 to 3).
The AUC for diagnostic catheterization has the potential
to impact physician decision making, healthcare delivery,
and reimbursement policy. Furthermore, it is hoped that rec-
ognition of uncertain clinical scenarios facilitates identifi-
cation of areas that could benefit from future research.
This report addresses the appropriate use of diagnostic
catheterization. Improvements in cardiovascular imaging
technology and an expanding array of noninvasive diagnostic
tools and therapeutic options for patients with cardiovascular
disease have led tomanymore choices than in the past. As the
field advances, the healthcare community needs tounderstand
how to best incorporate this technology into daily clinical
care. ACCF and SCAI are dedicated to this effort.2. METHODS
The indications included in this publication cover a variety
of cardiovascular signs and symptoms aswell as clinical judg-
ments as to the likelihood of cardiovascular findings. Within
each main disease category, a standardized approach was
used to capture a significant number of clinical scenarios
without making the list of indications excessive. The term
‘‘indication’’ is used interchangeably with ‘‘clinical sce-
nario’’ in thedocument for brevity and does not imply that im-
aging should necessarily be done. Diagnostic catheterization
may include several different procedure components. The in-
dications developed focused primarily on 2 aspects of diag-
nostic catheterization. Many indications focused on the
performance of coronary angiography for the detection of
coronary artery disease (CAD), with other procedure compo-
nents (eg, hemodynamic measurements, ventriculography)
performed at the discretion of the operator. The majority of
the remaining indications focused onhemodynamicmeasure-
ments to evaluatevalvular heart disease, pulmonaryhyperten-
sion, cardiomyopathy, and other conditions, with the addition
of coronary angiography at the discretion of the operator.ardiovascular Surgery c Volume 144, Number 1 41
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it would apply to the standard adult catheterization labora-
tory. Thewriting group did not consider invasive evaluations
of complex adult congenital heart disease in this document,
with the belief that such complex cases would be best
performed by individuals with considerable specialized ex-
pertise and at institutions with sufficient patient volume.
Recommendations in this area are addressed in separate sub-
specialty publications. Additionally, invasive procedures
such as endomyocardial biopsy, pericardiocentesis, or right
heart catheterization not performed in the catheterization
laboratory are not covered in this document.
The indications were constructed by a varied group of ex-
perts in both invasive and noninvasive diagnostic cardiac im-
aging. Subsequent modifications in the indications were
made based on discussions with the task force and feedback
from independent reviewers.Wherever possible, indications
weremapped to relevant clinical guidelines and key publica-
tions/references (see Online Appendix available at http://
content.onlinejacc.org/j.jacc.2012.03.003/DC2).
A detailed description of the methods used for rating
the selected clinical indications is found in a previous
publication, ‘‘ACCF Proposed Method for Evaluating
the Appropriateness of Cardiovascular Imaging.’’1 Briefly,
this process combines evidence-basedmedicine and practice
experience by engaging a technical panel in a modified Del-
phi exercise. The technical panel first rated the indications
independently, after which the results were summarized
and the panel convened for a face-to-face meeting to discuss
each indication. At this meeting, panel members were pro-
videdwith their scores and a blinded summary of their peers’
scores. After the meeting, panel members once again inde-
pendently rated each indication to determine the final scores.
Although panel members were not provided explicit cost
information to help determine their ratings, they were asked
to implicitly consider costs as an additional factor in their eval-
uation of appropriate use. In rating these criteria, the technical
panel was asked to assess whether the use of the test for each
indication is appropriate, uncertain, or inappropriate, and was
provided with the following definition of appropriate use:
An appropriate diagnostic cardiac catheterization (left
heart, right heart, ventriculography, and/or coronary angi-
ography) is one inwhich the expected incremental informa-
tion combined with clinical judgment exceeds the negative
consequences by a sufficiently wide margin for a specific
indication that the procedure is generally considered ac-
ceptable care and a reasonable approach for the indication.
Each member of the technical panel assigned a score to
each indication, and the scores of the technical panel were
tabulated for the final ratings and assigned an appropriate-
ness rating as follows:
Median Score 7 to 9
Appropriate test for specific indication (test is generally
acceptable and is a reasonable approach for the indication).42 The Journal of Thoracic and Cardiovascular SurgeMedian Score 4 to 6
Uncertain for specific indication (test may be generally
acceptable and may be a reasonable approach for the indi-
cation). Uncertainty also implies that more research and/or
patient information is needed to classify the indication
definitively.
Median Score 1 to 3
Inappropriate test for that indication (test is not generally
acceptable and is not a reasonable approach for the
indication).
The division of these scores into 3 levels of appropriate-
ness should be viewed as a continuum. It is important to em-
phasize that the category of ‘‘uncertain’’ is a distinct category
and must not be considered either ‘‘appropriate’’ or ‘‘inap-
propriate’’ or lumped together with the other categories
when characterizing appropriateness ratings. A rating of un-
certain will exist if: (1) there is considerable diversity in the
ratings among individual members of the technical panel in-
dicating a wide range of opinions; (2) there is insufficient
clinical information provided in the clinical scenario for
the raters to reach a firm conclusion about appropriateness;
or (3) there is a lack of specific information in the medical
literature to make a firm recommendation regarding appro-
priateness. The uncertain category designation should
encourage investigators to perform definitive research when-
ever possible. A designation of ‘‘uncertain’’ does not imply
that the test should not be used in a specific clinical scenario.
Many other factors known by the clinician and difficult to
characterizewithin the structure of theAUCcould affect a de-
cision to perform or not perform a procedure in a specific pa-
tient. It is anticipated that the AUC reports will continue to be
revised as further data are generated and information from
the implementation of the criteria is accumulated. The writ-
ing group recognizes that a large portion of routine medical
care would be rated as uncertain when held to the standards
of the AUC and therefore hope this rating is correctly inter-
preted and can be placed in proper context.
To prevent bias in the scoring process, the technical panel
was deliberately comprised of a minority of specialists in
cardiac catheterization. Specialists, although offering im-
portant clinical and technical insights, might have a natural
tendency to rate the indications within their specialty as
more appropriate than nonspecialists. In addition, care was
taken in providing objective, nonbiased information, includ-
ing guidelines and key references, to the technical panel.
The level of agreement among panelists as defined by
RAND2 was analyzed based on the BIOMED rule for
a panel of 14 to 16 members. As such, agreement is defined
as an indication where 4 or fewer panelists’ ratings fell out-
side the 3-point region containing the median score.
Disagreement was defined as where at least 5 panelists’
ratings fell in both the appropriate and the inappropriate cat-
egories. Any indication having disagreement was catego-
rized as uncertain regardless of the final median score.ry c July 2012
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To limit inconsistencies in interpretation, specific assump-
tions were used by the writing group in drafting indications
and by the technical panel when rating the clinical indica-
tions for the appropriate use of diagnostic catheterization.
1. The clinical scenarios were rated based on published
literature and clinical practice guidelines regarding the
risks and benefits of diagnostic catheterization, if
available. In general, there are few randomized trials spe-
cifically examining diagnostic catheterization as a proce-
dure. However, diagnostic catheterization was used
within the study design of many randomized trials in
which specific therapies were tested. Specific patient
groups not well represented in the literature are not pre-
sented in the current clinical scenarios. However, the
writing group recognizes that decisions about diagnos-
tic catheterization in such patients are frequently re-
quired. Examples of such patients include those with
end-stage renal disease, advanced age, or malignancy.
2. All patients are attempting to achieve optimal care, in-
cluding guideline-based risk factor modification for
primary or secondary prevention in cardiovascular
patients unless specifically noted.3-7
3. Despite the best efforts of the clinician, all patients may
not achieve target goals for risk factor modification.
However, a plan of care to address risk factors is as-
sumed to be occurring in patients represented in the in-
dications. For patients with chronic stable angina, the
writing group recognizes that there is a wide variance
in the medical therapy for angina.
4. Operators performing diagnostic catheterization have
appropriate clinical training and experience and have
satisfactory outcomes as assessed by quality assurance
monitoring.8,9
5. Diagnostic catheterization (left heart, right heart, and/
or coronary angiography) is performed in a manner
consistent with established standards of care.8,9
6. All indications for diagnostic catheterization were
considered with the following important assumptions:
a. All indications were first evaluated on the basis of the
available medical literature.
b. In many cases, studies published in the medical liter-
ature provide minimal information about the role of
the test in clinical decision making.
c. Appropriate use criteria development requires a risk/
benefit trade-off as determined by individual patient
indications. Radiation exposure should be considered
in risk estimates.
d. No circumstances exist that would preclude cardiac
catheterization (eg, severe coagulopathy, patient re-
fusal).
7. A complete clinical history and physical exam has been
completed by a qualified clinician such that the clinicalThe Journal of Thoracic and Cstatus of the patient can be assumed to be valid as stated
in the indication (eg, asymptomatic patient is truly
asymptomatic for the condition in question and that suf-
ficient questioning of the patient has been undertaken).
8. Cost was be considered implicitly in the appropriate use
determination.
9. For each indication, the rating reflected whether diag-
nostic catheterization is reasonable for the patient and
not whether it is preferred over another modality.
10. The category of ‘‘uncertain’’ was used when insuffi-
cient clinical data are available for a definitive catego-
rization or there is substantial disagreement regarding
the appropriateness of that indication. Those scenarios
designated as uncertain reflect variations in clinical
practice patterns. The designation of ‘‘uncertain’’
should not be used as grounds for denial of reim-
bursement.
11. All procedures presented are to be considered for clin-
ical indications and not part of a research protocol.
12. All prior noninvasive testing was adequately completed.
4. DEFINITIONS
Definitions of terms used throughout the indication set are
listed here. These definitions were provided to and discussed
with the technical panel prior to rating of indications.
Stress Testing and Risk of Findings on Noninvasive
Testing: Stress testing is commonly used for both diagnosis
(possible/presumed) and risk stratification of patients with
established CAD. Using criteria defined for traditional exer-
cise stress tests10,11:
 Low-risk stress test findings: associated with a cardiac
mortality of<1% per year
 Intermediate-risk stress test findings: associated with
a 1% to 3% per year cardiac mortality
 High-risk stress test findings: associated with a>3%
per year cardiac mortality
Symptomatic/Ischemic Equivalent: Chest Pain Syn-
drome, Anginal Equivalent, or Ischemic Electrocardio-
gram (ECG) Abnormalities: Any constellation of clinical
findings that the physician believes is consistent with CAD
manifestations. Examples of such findings include, but are
not limited to, chest pain, chest tightness, chest burning,
shoulder pain, left arm pain, jaw pain, new ECG abnormali-
ties, or other symptoms/findings suggestive of CAD. Clinical
presentations in the absence of chest pain (eg, dyspnea with
exertion or reduced/worsening effort tolerance) that are
thought to be consistent with CAD may also be considered
to be an ischemic equivalent.
Clinical Classification of Chest Pain:
 TypicalAngina (Definite): defined as (1) substernal chest
pain or discomfort that is (2) provoked by exertion or emo-
tional stress and (3) relieved by rest and/or nitroglycerin.12ardiovascular Surgery c Volume 144, Number 1 43
TABLE A. Pretest probability of CAD by age, gender, and symptoms*
Age (y) Gender
Typical/definite
angina pectoris
Atypical/probable
angina pectoris Nonanginal chest pain Asymptomatic
<39 Men Intermediate Intermediate Low Verylow
Women Intermediate Verylow Verylow Verylow
40-49 Men High Intermediate Intermediate Low
Women Intermediate Low Verylow Verylow
50-59 Men High Intermediate Intermediate Low
Women Intermediate Intermediate Low Verylow
>60 Men High Intermediate Intermediate Low
Women High Intermediate Intermediate Low
High:>90% pretest probability. Intermediate: between 10% and 90% pretest probability. Low: between 5% and 10% pretest probability. Very low:<5% pretest probability.
CAD, Coronary artery disease. *Modified from the ACC/AHA Exercise Testing Guidelines to reflect all age ranges.18
Clinical Guidelines Patel et al Atypical Angina (Probable): chest pain or discomfort
that lacks 1 of the characteristics of definite or typical an-
gina.
 Nonanginal Chest Pain: chest pain or discomfort that
meets 1 or none of the typical angina characteristics.
Grading of Angina Pectoris by the Canadian Cardio-
vascular Society Classification System13:
Class I: ordinary physical activity does not cause angina,
such as walking, climbing stairs. Angina occurs with
strenuous, rapid, or prolonged exertion at work or
recreation.
Class II: slight limitation of ordinary activity. Angina
occurs on walking more than 2 blocks on the level
and climbing more than 1 flight of ordinary stairs at
a normal pace and in normal condition.
Class III:marked limitations of ordinary physical activ-
ity. Angina occurs on walking 1 or 2 blocks on the
level and climbing 1 flight of stairs in normal condi-
tions and at a normal pace.
Class IV: inability to carry on any physical activity with-
out discomfort—anginal symptoms may be present at
rest.
Pretest Probability of Coronary Artery Disease: Symp-
tomatic (Ischemic Equivalent) Patients:Once the physician
determines that symptoms are present that may represent
CAD, the pretest probability of CAD should be assessed.
There are a number of risk algorithms14,15 available that can
be used to calculate this probability. Clinicians should be
familiar with those algorithms that pertain to the populations
they encounter most often. In rating the appropriateness
of cardiac catheterization for specific indications, the
following probabilities, as calculated from any of the
various available validated algorithms, should be applied10:
 Very low pretest probability:<5% pretest probability
of CAD
 Low pretest probability: between 5% and 10% pretest
probability of CAD44 The Journal of Thoracic and Cardiovascular Surge Intermediate pretest probability: between 10% and
90% pretest probability of CAD
 High pretest probability:>90% pretest probability of
CAD
The method recommended by the ACCF/AHA guide-
lines for chronic stable angina10 is provided as one example
of a method used to calculate pretest probability and is
a modification of a previously published literature re-
view.16 Please refer to Table A and the clinical classifica-
tion of chest pain definition angina characteristics. It is
important to note that other historical factors or ECG find-
ings (eg, prior infarction) can affect pretest probability, al-
though these factors are not accounted for in Table A.
Similarly, while not incorporated into the algorithm, other
CAD risk factors may also affect pretest likelihood of
CAD. Detailed nomograms are available that incorporate
the effects of a history of prior infarction, ECG Q waves
and ST- and T-wave changes, diabetes, smoking, and
hypercholesterolemia.17
Global CAD Risk: It is assumed that clinicians will use
current standard methods of global risk assessment such as
those presented in the National Heart, Lung, and Blood In-
stitute report on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel
III [ATP III])19 or similar national guidelines.
Absolute risk is defined as the probability of developing
CAD over a given time period. The ATP III report esti-
mates the absolute risk for CAD over the next 10 years.
CAD risk refers to 10-year risk for any hard cardiac event
(eg, myocardial infarction or CAD death). However, ac-
knowledging that global absolute risk scores may have
not been evaluated in certain populations (eg, women,
younger men, minority populations), clinical judgment
must be applied in assigning categorical risk thresholds
in such subpopulations.
 Low global CAD riskry c JDefined by the age-specific risk level that is below av-
erage. In general, low risk will correlate with a 10-year
absolute CAD risk<10%. However, in women anduly 2012
FIGUREA. Stepwise approach to perioperative cardiac assessment. Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical
conditions, known cardiovascular disease, or cardiac risk factors for patients 50 years of age. HR, Heart rate; LOE, level of evidence; MET, metabolic
equivalent. Modified from Fleisher et al.22
Patel et al Clinical Guidelinesyounger men, low risk may correlate with 10-year ab-
solute CAD risk<6%. Intermediate global CAD risk
Defined by the age-specific risk level that is average.
In general, moderate risk will correlate with a 10-
year absolute CAD risk range of 10% to 20%. Among
women and younger men, an expanded intermediate
risk range of 6% to 20% may be appropriate. High global CAD risk
Defined by the age-specific risk level that is above
average. In general, high risk will correlate with
a 10-year absolute CAD risk of>20%. CAD equiva-
lents (eg, diabetes mellitus, peripheral arterial disease)
can also define high risk.DukeTreadmill Score20: The equation for calculating the
Duke treadmill score (DTS) is DTS¼ exercise time in min-
utes (5 3 ST-segment deviation) (4 3 exercise angina),
with 0 ¼ none, 1 ¼ nonlimiting, and 2 ¼ exercise-limiting.
The score typically ranges from25 toþ15. These values
correspond to low-risk (with a score ofþ5), moderate-risk
(with scores ranging from10 toþ4), and high-risk (with
a score of 11) categories.
ECG—Uninterpretable: Refers to ECGs with resting
ST-segment depression (0.10 mV), left bundle branch
block (LBBB), pre-excitation (Wolff-Parkinson-White
Syndrome), or paced rhythm.The Journal of Thoracic and CAdjunct Invasive Diagnostic Testing:
 Fractional flow reserve (FFR)ardiAn invasive diagnostic tool used to provide physiolog-
ical measurements as an adjunct to coronary angiogra-
phy for the determination of lesion severity and to
assist in decisions about revascularization. FFR is cal-
culated using the ratio of the mean arterial pressure
distal to a stenosis to the mean aortic pressure during
maximal hyperemia. FFR measurements<0.75 are as-
sociated with ischemia on exercise testing and adjunct
imaging (echo or nuclear) with high sensitivity (88%),
specificity (100%), and overall accuracy (93%). FFR
measurements>0.80 are associated with negative is-
chemic results with a predictive accuracy of 95%.
Routine measurement of FFR in patients with multi-
vessel coronary artery disease who are undergoing
PCI with drug-eluting stents with deferral of lesions
with FFR>0.80 has been shown to significantly re-
duce the rate of the composite endpoint of death,
nonfatal myocardial infarction, and repeat revascular-
ization at 1 year.21 Intravascular ultrasound
An invasive diagnostic test performed as an adjunct to
diagnostic catheterization to provide an ultrasound-
based anatomic assessment that extends beyond con-
ventional angiography. This technique is used to
identify lesion and vessel characteristics and obtainovascular Surgery c Volume 144, Number 1 45
TABLE B. Active cardiac conditions for which the patient should undergo evaluation and treatment before noncardiac surgery (class I, level of
evidence: B)
Condition Examples
Unstable coronary syndromes Unstable or severe angina* (CCS class III or IV)y
Recent MIz
Decompensated HF (NYHA functional class IV;
worsening or new-onset HF)
Significant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including atrial fibrillation) with uncontrolled ventricular rate (HR
>100 beats/min at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
Severe valvular disease Severe aortic stenosis (mean pressure gradient>40 mm Hg, aortic valve area<1.0 cm2, or
symptomatic)
Symptomatic mitral stenosis (progressive dyspnea on exertion, extertional presyncope, or HF)
Reprinted from Fleisher et al.22 CCS, Canadian Cardiovascular Society; HF, heart failure; HR, heart rate; MI, myocardial infarction; NYHA, New York Heart Association.
*According to Campeau13; ymay include ‘‘stable’’ angina in patients who are unusually sedentary; zthe American College of Cardiology National Database Library defines recent
MI as>7 days but 1 month (within 30 days).
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46basic measurements for diagnostic and interventional
application (minimal and maximal luminal diame-
ters, cross-sectional area, and plaque area).Evaluating Perioperative Risk for Noncardiac Sur-
gery: See Figure A, ‘‘Stepwise Approach to Perioperative
Cardiac Assessment,’’ from the ACCF/AHA 2009 perioper-
ative guidelines.22 According to the algorithm, once it is de-
termined that the patient does not require urgent surgery, the
clinician should determine the patient’s active cardiac con-
ditions (see Table B) and/or perioperative risk predictors
(see Table C). If any active cardiac conditions and/or major
risk predictors are present, Figure A suggests consideration
of guideline-based care that may include coronary angiog-
raphy and postponing or canceling noncardiac surgery.
Once perioperative risk predictors are assessed, the surgical
risk and the patient’s functional status should be used to es-
tablish the need for noninvasive testing.5. ABBREVIATIONS
ACS ¼ acute coronary syndrome
AV ¼ atrioventricular
CABG ¼ coronary artery bypass grafting surgery
CAD ¼ coronary artery diseaseE C. Perioperative clinical risk factors*
tory of ischemic heart disease
tory of compensated or prior heart failure
tory of cerebrovascular disease
betes mellitus (requiring insulin)
al insufficiency (creatinine>2.0)
American College of Cardiology Foundation; AHA, American Heart Associ-
*As defined by the ACCF/AHA guidelines on perioperative cardiovascular
ion and care for noncardiac surgery.22 Note that these are not standard coro-
tery disease risk factors.
The Journal of Thoracic and Cardiovascular SurgeECG ¼ electrocardiogram
FFR ¼ fractional flow reserve
LBBB ¼ left bundle branch block
LV ¼ left ventricular6. RESULTS OF RATINGS
The final ratings for diagnostic catheterization are listed
by indication in Tables 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 2.1,
2.2, 2.3, to 3.1. The final score reflects the median score of
the 17 technical panel members and has been labeled
according to the 3 appropriate use categories of
appropriate (median 7 to 9), uncertain (median 4 to 6), and
inappropriate (median 1 to 3). Tables 4, 5, and 6 present
the same indications by the appropriate use categories.7. DIAGNOSTIC CATHETERIZATION
APPROPRIATE USE CRITERIA (BY INDICATION)
A. CAD Assessment
1. Coronary Angiography With or Without Left
Heart Catheterization and Left Ventriculography
Coronary angiography is widely used to evaluate pa-
tients with known or suspected CAD. Depending on
the clinical circumstances and prior testing, coronary
angiography may be coupled with the measurement
of left ventricular (LV) pressures (left heart catheter-
ization) and/or the evaluation of LV systolic function
and wall motion (left ventriculography).
The indications developed in Section A relate to ap-
propriateness of coronary angiography. A decision
about the performance of left heart catheterization
and left ventriculography is left to the discretion of
the operator and the patient’s primary physician.ry c July 2012
TABLE 1.1. Suspected or known ACS
A, Appropriate; ACS, acute coronary syndrome; GRACE, Global Registry of Acute Coronary Events; LV, left ventricular; STEMI, ST-elevation myocardial infarction; TIMI,
Thrombolysis In Myocardial Infarction; UA/NSTEMI, unstable angina non–ST-elevation myocardial infarction.
TABLE 1.2. Suspected CAD: No prior noninvasive stress imaging (no prior PCI, CABG, or angiogram showing 50% angiographic stenosis)
A, Appropriate; CABG, coronary bypass grafting surgery; CAD, coronary artery disease; I, inappropriate; PCI, percutaneous coronary intervention; U, uncertain.
TABLE 1.3. Suspected CAD: Prior noninvasive testing (no prior PCI, CABG, or angiogram showing 50% angiographic stenosis)
(Continued)
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A, Appropriate; CABG, coronary bypass grafting surgery; CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; CTA, computed tomography angiography;
ECG, electrocardiogram; I, inappropriate; LV, left ventricular; LVEF, left ventricular ejection fraction; PET, positron emission tomography; SPECT MPI, single-photon emission
computed tomography myocardial perfusion imaging; TID, transient ischemic dilation; TTE, transthoracic echocardiography; U, uncertain; VSD, ventricular septal defect.
*Coronary calcium score only rated for asymptomatic patients as these patients are the population in which it is used.
TABLE 1.4. Adjunctive invasive diagnostic testing in patients undergoing appropriate diagnostic coronary angiography
A, Appropriate; FFR, fractional flow reserve; I, inappropriate; IVUS, intravascular ultrasound;U, uncertain. *Concordance refers to noninvasive imaging studies that demonstrate
evidence of abnormal myocardial perfusion that is in the same distribution as a coronary artery stenosis, or degree of valvular disease that is similar to clinical impression.
TABLE 1.3. Continued
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TABLE 1.5. Patients with known obstructive CAD (eg, prior MI, prior PCI, prior CABG, or obstructive disease on invasive angiography)
A, Appropriate; CABG, coronary bypass grafting surgery; CAD, coronary artery disease; I, inappropriate; MI, myocardial infarction; PCI, percutaneous coronary intervention;
U, uncertain.
TABLE 1.6. Arrhythmias
A, Appropriate; AV, atrioventricular; CHD, coronary heart disease; I, inappropriate; LBBB, left bundle branch block; LV, left ventricular;U, uncertain; VF, ventricular fibrillation;
VT, ventricular tachycardia.
TABLE 1.7. Preoperative coronary evaluation for noncardiac surgery in stable patients
Cr, Creatinine; I, inappropriate; METS, metabolic equivalents; U, uncertain.
Patel et al Clinical Guidelines
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Artery Disease
2. Right and Left Heart Catheterization or Right
Heart Catheterization Alone With or Without
Left Ventriculography and Coronary Angiogra-
phy
Right and left heart catheterization (including the
measurement of cardiac output and intracardiac oxy-
gen saturations) is used to evaluate a variety of condi-
tions. The syndrome of heart failure may or may not
be present in these clinical scenarios. Depending on
the clinical circumstances and prior testing, coronary
angiography, left or right ventriculography, and addi-
tional angiography such as supravalvular aortography
may be coupled with hemodynamic measurements. A
decision about the need for coronary angiography in
addition to the hemodynamic study should be at the
discretion of the operator and the patient’s primary
physician.
2.1. Valvular Disease
Patients with valvular heart disease can be chal-
lenging to evaluate, and these challenges are
even greater in the setting of multivalve involve-
ment. Failure to intervene with appropriate thera-
pies at the correct time can result in the
permanent impairment of heart function and
a poor prognosis. The evaluation of valvular dis-
ease should start with a careful history and physi-
cal examination and is then augmented by
noninvasive imaging, most frequently echocardi-
ography. One of the challenges faced by clinicians
occurs when the clinical impression of valve le-
sion severity based on the history and physical
exam differs from that derived from an imagingTABLE 2.1. Valvular disease
50 The Journal of Thoracic and Cardiovascular Surgerytest. The presence of concordant or conflicting im-
pressions may affect the decision to perform an in-
vasive evaluation and this is tested in the table
below. For patients in whom valve surgery is
planned, the indication for cardiac catheterization
is covered in Indication 70.
Table 2.1 only considers isolated lesions of left-
sided valves and does not consider mixed disease
of a valve (eg, aortic stenosis and regurgitation)
or multivalve disease. Invasive evaluation may
be necessary in these settings but often requires
the assessment of several other variables such as
LV function and should be at the discretion of
the clinician. Scenarios were not developed for
isolated or mixed disease of the tricuspid or pul-
monic valve because they are relatively uncom-
mon in adults and, when present, are often
associated with left-sided valve lesions.
2.2. Cardiomyopathies
A variety of conditions present with signs and/or
symptoms of heart failure. Right heart catheteriza-
tion alone or combined right and left heart catheter-
ization (including the measurement of cardiac and
pulmonary pressures, cardiac output, vascular resis-
tance, and intracardiac oxygen saturations) is used
to evaluate many of these conditions. Depending
on the clinical circumstances and prior testing, cor-
onary angiography, left or right ventriculography,
and additional angiography may be coupled with
these hemodynamic measurements. The indications
developed below relate to appropriateness of the
right and left heart catheterization. A decision about
the performance of coronary angiography should be
at the discretion of the operator and the patient’s
primary physician.(Continued)
c July 2012
TABLE 2.2. Pericardial diseases
A, Appropriate.
A, Appropriate; I, inappropriate; U, uncertain.
TABLE 2.3. Cardiomyopathies
A, Appropriate; U, uncertain.
TA
A, A
TABLE 2.1. Continued
Patel et al Clinical Guidelines3. Right Heart Catheterization
In several clinical situations, the performance of right
heart catheterization (hemodynamics and cardiacBLE 3.1. Pulmonary hypertension or intracardiac shunt evaluation
ppropriate.
The Journal of Thoracic and Caroutput) alone is used. This can be performed in the
cardiac catheterization laboratory.diovascular Surgery c Volume 144, Number 1 51
Clinical Guidelines Patel et al8. DIAGNOSTIC CATHETERIZATION APPROPRIATE USE CRITERIA (BYAPPROPRIATE USE RATING)TABLE 4. Appropriate indications (median score 7–9)
(Continued)
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TABLE 4. Continued
(Continued)
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A, Appropriate; ACS, acute coronary syndrome; CABG, coronary bypass grafting surgery; CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; CTA, com-
puted tomography angiography; ECG, electrocardiogram; FFR, fractional flow reserve; GRACE, Global Registry of Acute Coronary Events; IVUS, intravascular ultrasound; LV,
left ventricular; LVEF, left ventricular ejection fraction;MI, myocardial infarction; PET, positron emission tomography; PCI, percutaneous coronary intervention; SPECT MPI,
single-photon emission computed tomography myocardial perfusion imaging; STEMI, ST-elevation myocardial infarction; TID, transient ischemic dilation; TIMI, Thrombolysis
In Myocardial Infarction; TTE, transthoracic echocardiography; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; VF, ventricular fibrillation; VSD, ven-
tricular septal defect; VT, ventricular tachycardia.
TABLE 5. Uncertain indications (median score 4–6)
TABLE 4. Continued
(Continued)
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TABLE 5. Continued
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AV, Atrioventricular;CABG, coronary bypass grafting surgery;CAD, coronary artery disease;CHD, coronary heart disease;CMR, cardiovascularmagnetic resonance;Cr, creatinine;
CTA, computed tomography angiography; ECG, electrocardiogram; FFR, fractional flow reserve; IVUS, intravascular ultrasound; LBBB, left bundle branch block; LV, left ventric-
ular; LVEF, left ventricular ejection fraction;METS, metabolic equivalents;MI, myocardial infarction; PCI, percutaneous coronary intervention; PET, positron emission tomogra-
phy; SPECT MPI, single-photon emission computed tomography myocardial perfusion imaging; TTE, transthoracic echocardiography; U, uncertain; VT, ventricular tachycardia.
TABLE 6. Inappropriate indications (median score 1–3)
TABLE 5. Continued
(Continued)
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AV, atrioventricular; CABG, coronary bypass grafting surgery; CAD, coronary artery disease; CHD, coronary heart disease; CMR, cardiovascular magnetic resonance; Cr, cre-
atinine; CTA, computed tomography angiography; ECG, electrocardiogram; FFR, fractional flow reserve; I, inappropriate; IVUS, intravascular ultrasound; METS, metabolic
equivalents; MI, myocardial infarction; PCI, percutaneous coronary intervention; PET, positron emission tomography; SPECT MPI, single-photon emission computed tomog-
raphy myocardial perfusion imaging.
TABLE 6. Continued
Patel et al Clinical Guidelines9. FIGURESFIGURE 1. Suspected CAD: No prior noninvasive stress imaging. A, Ap-
propriate; CAD, coronary artery disease; I, inappropriate; U, uncertain.The Journal of Thoracic and Cardiovascular Surgery c Volume 144, Number 1 59
FIGURE 2. Suspected CAD: Prior noninvasive stress testing. Indications 22 to 27 not covered in figure. CAD, Coronary artery disease; ECG, electrocar-
diography.
FIGURE 3. Suspected CAD: Prior noninvasive cardiac CT (calcium score and CTA). *Coronary calcium score only rated for asymptomatic patients as
these patients are the population in which it is used. CT, Computed tomography; CTA, computed tomography angiography.
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FIGURE 4. Patients with known obstructive CAD. CAD, Coronary artery disease; PCI, percutaneous coronary intervention.
FIGURE 5. Evaluation of arrhythmias. Indication 63 for newly diagnosed LBBB is not represented in this figure and was rated as ‘‘uncertain.’’ CHD, Cor-
onary heart disease; LBBB, left bundle branch block; LV, left ventricular; NI, noninvasive; VF, ventricular fibrillation; VT, ventricular tachycardia.
Patel et al Clinical Guidelines
The Journal of Thoracic and Cardiovascular Surgery c Volume 144, Number 1 61
FIGURE 6. Preoperative coronary evaluation: Patients with no prior noninvasive stress testing. METS, Metabolic equivalents.
FIGURE 7. Evaluation of valvular disease. Preoperative assessment before valvular surgery is not represented in this figure and is rated ‘‘appropriate.’’
*Indication 90 for acute moderate or severe mitral or aortic regurgitation is not represented in this figure. Rating for concordant imaging is ‘‘uncertain’’
and conflicting imaging is ‘‘appropriate.’’ NI, Noninvasive.
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Diagnostic cardiac catheterization incorporates both im-
aging and hemodynamic procedures aimed at providing in-
formation to document specific cardiovascular disease
states as well as help care for and improve the health of pa-
tients with known or suspected heart disease. The AUC are
meant to provide guidance concerning the rational and
timely use of diagnostic cardiac catheterization and coro-
nary angiography. The current document provides an eval-
uation of many of the indications commonly considered
in clinical practice. The writing group felt that review of
the recommendations by general procedures and indications
would be of the highest utility to clinical practice.10.1. Assessment for CAD
Several sets of indications were rated regarding the use of
invasive coronary angiography for the evaluation of CAD.
The writing group felt that the decision to include left heart
catheterization, left ventriculography, and perhaps other in-
vasive procedures with coronary angiography should be at
the discretion of the operator, depending on the clinical sit-
uation, the presence or absence of noninvasive assessments
of LV function and pulmonary pressures, and the perceived
accuracy of these noninvasive results.
In general, these indications were grouped by the clinical
suspicion for acute coronary syndromes, suspected or
known obstructive CAD, use of adjunctive invasive diag-
nostic technologies, evaluation of arrhythmias, and preoper-
ative evaluation. Although these scenarios represented
many common clinical indications for the evaluation of
CAD, the writing group acknowledges that this is not com-
prehensive and thus there are likely clinical scenarios en-
countered in practice that are not rated in this document.
Nevertheless, review of these scenarios should provide cli-
nicians guidance on the use of coronary angiography.
Overall, patients with definite or suspected acute coro-
nary syndromes were rated as appropriate for coronary an-
giography. These ratings reflect the current management
and risk stratification of patients with acute coronary syn-
drome (ACS), which usually involves defining the presence,
location, and degree of coronary stenosis and is based on
abundant clinical studies on the management of ACS pa-
tients that used coronary angiography. Alternatively, in pa-
tients without known CAD, referral directly for coronary
angiography for the suspicion of obstructive disease was
felt to be appropriate only in symptomatic patients with
a high pretest probability. The remaining patients (asymp-
tomatic patients and symptomatic patients with low or inter-
mediate pretest probability) were felt to be uncertain or
inappropriate for a management strategy that used coronary
angiography as the initial diagnostic test.
In patients with prior noninvasive testing, coronary angi-
ography was rated inappropriate for asymptomatic patientsThe Journal of Thoracic and Cwith low-risk findings. Symptomatic patients with interme-
diate- or high-risk findings or equivocal/discordant nonin-
vasive findings were rated appropriate for coronary
angiography. Coronary calcium scores, regardless of sever-
ity, were rated as inappropriate indications for invasive cor-
onary angiography in asymptomatic patients. The technical
panel was not asked to rate calcium scores in symptomatic
patients as this test is usually only performed in asymptom-
atic patients to assess risk. For patients with known CAD,
asymptomatic patients following revascularization and
medically managed patients with stable symptoms and
low-risk noninvasive test findings were rated inappropriate
in general for coronary angiography, whereas patients with
high-risk noninvasive findings or those with limiting or
worsening symptoms were rated as appropriate.
Several clinical scenarios related to the use of coronary
angiography in the evaluation of certain cardiac arrhyth-
mias were developed. Coronary angiography was rated as
appropriate for patients resuscitated after cardiac arrest (as-
suming return of reasonable neurologic function) and for
those with sustained VT regardless of symptoms. The other
scenarios developed related to syncope, new onset atrial fi-
brillation/flutter, high-degree atrioventricular block, or new
LBBB and were generally inappropriate for patients with
a low coronary heart disease (CHD) risk and uncertain
with a high CHD risk.
Scenarios for patients scheduled for noncardiac surgical
procedures were also rated. In the preoperative setting for
noncardiac surgery, direct catheterization and angiography
was not generally considered appropriate unless the patient
had significant risk factors or was undergoing transplanta-
tion of a solid organ or vascular surgery.
10.2. Assessment for Conditions Other Than CAD
Assessment of intracardiac and pulmonary pressures and
other testing such as measurement of cardiac output were
evaluated primarily in the setting of valvular heart disease,
cardiomyopathies, and pulmonary hypertension. In the sec-
tion on CAD assessment, the scenarios developed consid-
ered the use of coronary angiography and considered
other procedures during the invasive evaluation (eg, left
heart catheterization, left ventriculography) as secondary
to the primary purpose of the evaluation and at the discre-
tion of the operator. In a similar format, the scenarios devel-
oped in this section rated the use of the hemodynamic
evaluations and considered coronary angiography as sec-
ondary to the primary purpose of the evaluation and at the
discretion of the operator.
It should be noted that, in general, for patients with
planned valvular surgery, preoperative catheterization for
coronary anatomy was rated as appropriate. Additionally,
in patients with symptomatic and severe valvular heart dis-
ease with discordant clinical and noninvasive imaging find-
ings, hemodynamic assessment was rated as appropriate.ardiovascular Surgery c Volume 144, Number 1 63
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ent, depressed LV function or decreased cardiac output
were rated as appropriate for further evaluation using hemo-
dynamic studies.
Patients without symptoms, with mild to moderate steno-
sis or concordant clinical and noninvasive findings were
generally rated as inappropriate for diagnostic catheteriza-
tion procedures with hemodynamic assessment. Those
without symptoms but with severe disease were rated as un-
certain. Asymptomatic patients with valvular heart disease
were rated based on the noninvasive findings alone since
discordance between a clinical impression and noninvasive
findings in these patients would not be easily determined.
Patients with pulmonary hypertension, either clinically sus-
pected or documented and requiring evaluation for pharma-
cological therapy, were identified as appropriate for
invasive hemodynamic assessment at rest as well as with
provocative maneuvers (exercise or pharmacological
challenge).
Specific groups such as those suspected of pericardial
disease, intracardiac shunts, tamponade, suspected cardio-
myopathy or patients who have received cardiac transplant
were rated as appropriate for hemodynamic studies and en-
domyocardial biopsy.
10.3. Application of the Criteria
In their work developing and rating these clinical scenar-
ios, the writing group and technical panel focused on the
multiple goals of diagnostic cardiac catheterization and cor-
onary angiography and common clinical scenarios seen in
clinical practice. Clinical scenarios and ultimately the rat-
ings of the technical panel were focused on obtaining infor-
mation from the procedure that should help in the
management of patients with suspected or known heart dis-
ease including providing needed reassurance about the clin-
ical status of the patient. Additionally, the diagnostic
catheterization AUCwas written with recognition that these
indications would be linked with the coronary revasculari-
zation AUC. In fact, the hope of the writing group was to
develop a system that would inform patients and clinicians
to increase the right patients undergoing appropriate inva-
sive catheterization procedures before discussions and con-
siderations around revascularization.
With these goals in mind, there are many potential appli-
cations for the AUC in this document. Decision support and
educational tools should be developed. Ideally, these would
translate these ratings into clinical tools used at the point of
care to aid clinicians and patients in the decision to perform
or undergo an invasive procedure. Figures 1 to 7 are meant
to provide some initial algorithms for the overall ratings.
Facilities and payers may choose to use these criteria, ei-
ther prospectively in the design of protocols or review pro-
cedures, or retrospectively for quality reports. It is hoped
that payers would use these criteria to ensure that their64 The Journal of Thoracic and Cardiovascular Surgemembers receive necessary, beneficial, and cost-effective
cardiovascular care, rather than for other purposes. It is ex-
pected that services performed for appropriate and/or uncer-
tain indications will receive reimbursement. In contrast,
services performed for inappropriate indications may re-
quire additional documentation to justify payment because
of the unique circumstances or the clinical profile that may
exist in such a patient. This additional documentation
should not be required for uncertain indications. It is critical
to emphasize that the writing group, technical panel, AUC
Task Force, and clinical community do not believe an un-
certain rating justifies denial of reimbursement for these in-
vasive procedures. Rather, uncertain ratings are those in
which the available data vary and many other factors exist
that may affect the decision to perform or not perform car-
diac catheterization and coronary angiography. The opin-
ions of the technical panel often varied for these
indications, reflecting that additional research is needed. In-
dications with high clinical volume that are rated as uncer-
tain identify important areas for further research. The
writing group and technical panel favor the collaborative in-
teraction between patients, referring clinicians, and cardiol-
ogists in determining the need for these invasive
procedures.
When evaluating physician or facility performance, AUC
should be used in conjunction with efforts that lead to qual-
ity improvement. Prospective preauthorization procedures,
if put in place, are most effective once a retrospective re-
view has identified a pattern of potential inappropriate
use. Because these criteria are based on current scientific
evidence and the deliberations of the technical panel, they
should be used prospectively to generate future discussions
about reimbursement, but should not be applied retrospec-
tively to cases completed before issuance of this report or
documentation of centers/providers performing an unex-
pectedly high proportion of inappropriate cases as com-
pared with their peers.
The writing group recognizes that these criteria will be
evaluated during routine clinical care. To that end, specific
data fields such as symptom status, presence or absence of
acute coronary syndrome, history of CAD or revasculariza-
tion, and type of noninvasive testing and findings will be re-
quired to determine individual appropriate use ratings. It is
recognized that the characterization of symptoms is inher-
ently subjective, and there is variability in the interpretation
of many noninvasive tests. Fundamental to the application
of the AUC is the understanding that the characterization
of symptoms or interpretation of noninvasive tests is per-
formed in a manner such that independent qualified re-
viewers would reach the same conclusions or support the
conclusions of the individual physician about symptoms
or noninvasive test results.
The primary objective of this report is to provide guid-
ance regarding the use of diagnostic catheterizationry c July 2012
Patel et al Clinical Guidelinesincluding coronary angiography, left heart catheterization
and left ventriculography, and right heart catheterization
for a diverse set of clinical scenarios. As with previous
AUC documents, consensus among the raters was desirable,
but an attempt to achieve complete agreement within this
diverse panel would have been artificial and was not the
goal of the process. Two rounds of ratings with substantial
discussion among the technical panel members between the
ratings did lead to some consensus among panelists. How-
ever, further attempts to drive consensus would have diluted
true differences in opinion among panelists and, therefore,
was not undertaken.
Future research analyzing patient outcomes for indica-
tions rated as appropriate and inappropriate will help ensure
the equitable and efficient allocation of resources for car-
diac catheterization. Further exploration of the indications
rated as ‘‘uncertain’’ will help generate the information re-
quired to further define the appropriate use of cardiac cath-
eterization procedures. Additionally, the criteria will need
to be updated with the publication of ongoing trials in imag-
ing and revascularization occurs.
In conclusion, this document represents the current un-
derstanding of the clinical utility of diagnostic cardiac cath-
eterization. It is intended to provide a practical guide to
clinicians and patients when these procedures.APPENDIX A. ADDITIONAL DIAGNOSTIC
CATHETERIZATION DEFINITIONS
TIMI Risk Score—For Patients With Suspected ACS23:
Variables (1 point each)
 Age 65 years
 3 risk factors (hypertension, diabetes mellitus, family
history, lipids, smoking)
 Known CAD (stenosis 50%)
 Aspirin use in past 7 days
 Severe angina (2 episodes within 24 hours)
 ST-segment deviation 0.5 mm
 Elevated cardiac markers
Risk of death or ischemic event through 14 days
 Low: 0 to 2 (<8.3% event rate)
 Intermediate: 3 to 4 (<19.3% event rate)
 High: 5 to 7 (41% event rate)
GRACE ACS Risk Model24:
At admission (in-hospital/to 6 months)
 Age
 Heart rate
 Systolic blood pressure mm Hg
 Creatinine
 Congestive heart failure Killip class
 Cardiac arrest at admission
 ST-segment deviationThe Journal of Thoracic and C Elevated cardiac enzymes/markers
At discharge (to 6 months)
 Age
 Heart rate
 Systolic blood pressure mm Hg
 Creatinine
 Congestive heart failure
 In-hospital PCI
 In-hospital CABG
 Past history of myocardial infarction
 ST-segment depression
 Elevated cardiac enzymes/markersAPPENDIX B. ADDITIONAL METHODS
Relationships With Industry and Other Entities
The American College of Cardiology Foundation and the
Society for Cardiovascular Angiography and Interventions
and its partnering organizations rigorously avoid any actual,
perceived, or potential conflicts of interest that might arise
as a result of an outside relationship or personal interest
of a member of the technical panel. Specifically, all panel-
ists were asked to provide disclosure statements of all rela-
tionships that might be perceived as real or potential
conflicts of interest. These statements were reviewed by
the Appropriate Use Criteria Task Force, discussed with
all members of the technical panel at the face-to-face meet-
ing, and updated and reviewed as necessary. A table of dis-
closures by all participants, listed in Appendix C, in the
Appropriate Use Criteria for Diagnostic Catheterization
can be found in Appendix D. In addition, to ensure complete
transparency, complete disclosure information (available
online at: http://content.onlinejacc.org/j.jacc.2012.03.003/
DC1)—including relationships not pertinent to this docu-
ment—is available online as a document supplement.Literature Review
The technical panel members were asked to refer to the
relevant guidelines for a summary of the relevant literature,
guideline recommendation tables, and reference lists pro-
vided for each indication table when completing their rat-
ings (Online Appendix available at: http://content.
onlinejacc.org/j.jacc.2012.03.003/DC2).APPENDIX C. ACCF/SCAI/AATS/AHA/ASE/ASNC/
HFSA/HRS/SCCM/SCCT/SCMR/STS 2012
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York, NY
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Medicine, University of Wisconsin, Madison and Medical
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San Diego School of Medicine, Staff Physician, VA Medi-
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Medicine and Surgery, University of Washington School of
Medicine, Director, UW Medicine Regional Heart Center,
Seattle, Wash
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Susan G. Lakoski, MD, MS—Assistant Professor, Uni-
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Dallas, Tex
D. Elizabeth Le, MD, FACC, FASE—Assistant Professor
of Medicine, Oregon Health and Science University, Staff
Physician, Portland VA Medical Center, Portland, Ore
John R. Lesser, MD, FACC, FSCAI, FSCCT—Director
of Cardiovascular MRI and CT, Minneapolis Heart Insti-
tute, Adjunct Associate Professor of Medicine, University
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Medicine, Baylor College of Medicine, Director, Cardiac
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